MAPK
Les MAPK sont une famille de kinases protéiques impliquées dans une variété de processus cellulaires, y compris la croissance, la prolifération, la différenciation et les réponses au stress. La voie de signalisation MAPK comprend plusieurs niveaux, y compris ERK, JNK et p38 MAPK, chacun jouant des rôles distincts dans la fonction cellulaire. La dérégulation de la signalisation MAPK est liée au cancer, aux maladies inflammatoires et aux troubles métaboliques. Chez CymitQuimica, nous offrons un large éventail d'inhibiteurs et d'activateurs de MAPK pour soutenir vos recherches en biologie cellulaire, transduction de signaux et mécanismes des maladies.
886 produits trouvés pour "MAPK"
Trier par
Degré de pureté (%)
0
100
|
0
|
50
|
90
|
95
|
100
RAS/RAS-RAF-IN-1
CAS :<p>RAS/RAS-RAF-IN-1: Potent RAS & RAS-RAF inhibitor, KD 5-15μM for CYPA, antitumor properties.</p>Formule :C45H57N7O7Couleur et forme :SolidMasse moléculaire :807.993JNK-IN-18
<p>JNK-IN-18 (compound 23b) is a potent inhibitor of JNK1, boasting an IC50 of 2 nM. It demonstrates superior efficacy when compared to its IC50 values of 125 nM for JNK2 and 98 nM for BRAF(V600E).</p>Couleur et forme :Odour SolidKRAS G12D inhibitor 15
CAS :<p>Potent KRAS G12D inhibitor 15 targets cancer, potential for disease research. (WO2022042630A1, compound 243)</p>Formule :C53H71F2N7O5Couleur et forme :SolidMasse moléculaire :924.17NEK7-IN-1
CAS :<p>NEK7-IN-1 (Compound I-15) is an inhibitor of NIMA-related kinase 7 (NEK7) with an IC50 of less than 100 nM. It also effectively inhibits the release of IL-1β, exhibiting an IC50 of less than 50 nM.</p>Formule :C30H34F4N8O2Couleur et forme :SolidMasse moléculaire :614.64RTIL 13
CAS :<p>RTIL 13 inhibits dynamin GTPase (IC50: 2.3 μM), targets its lipid binding domain, and suppresses endocytosis (IC50: 9.3 & 7.1 μM).</p>Formule :C30H55BrN2O3Couleur et forme :SolidMasse moléculaire :571.685SIAIS562055
<p>SIAIS562055, a potent cereblon-based SOS1PROTAC, exhibits a dissociation constant (Kd) of 95.9 nM. It effectively degrades SOS1 and inhibits the downstream ERK pathway. SIAIS562055 disrupts the interaction between KRASG12C or KRASG12D and SOS1, with IC50 values of 95.7 nM and 134.5 nM, respectively. This compound demonstrates strong anticancer activity.</p>Formule :C49H62F3N7O5SCouleur et forme :SolidMasse moléculaire :918.12Tagarafdeg
CAS :<p>Tagarafdeg (CFT1946) is a PROTAC degradator targeting mutant BRAF, capable of degrading BRAF V600E, G469A, G466V mutations, anti proliferation.</p>Formule :C45H49F2N11O9SDegré de pureté :＞99.99%Couleur et forme :SolidMasse moléculaire :958Ras Inhibitory Peptide acetate
<p>Ras Inhibitory Peptide acetate, involved in cancer-related Ras signaling.</p>Formule :C55H95N19O13Degré de pureté :96.63%Couleur et forme :SolidMasse moléculaire :1230.46PROTAC K-Ras Degrader-5
CAS :<p>Pan-KRAS degrader 4 (compound 69) is a cereblon-based PROTAC KRAS degrader exhibiting anticancer activity with a DC50 value of less than 100 nM.</p>Formule :C57H63F3N10O5Couleur et forme :SolidMasse moléculaire :1025.17Pan-RAS-IN-7
CAS :<p>Pan-RAS-IN-7 (Compound D101) is a broad-spectrum RAS inhibitor used in the synthesis of antibody-drug conjugates (ADCs). It is also applicable in cancer research.</p>Formule :C59H76N8O8Couleur et forme :SolidMasse moléculaire :1025.28PROTAC SOS1 degrader-4
<p>PROTAC SOS1 Degrader-4 (compound 10) is a potent degrader of SOS1 and exhibits antiproliferative activity [1].</p>Formule :C53H65ClN8O7SDegré de pureté :98%Couleur et forme :SolidMasse moléculaire :993.65PPM-3
<p>PPM-3, a selective PROTAC ERK5 degrader, exhibits a potent inhibitory concentration (IC 50) of 62.4 nM.</p>Formule :C54H69N11O6SDegré de pureté :98%Couleur et forme :SolidMasse moléculaire :1000.26U0124
CAS :<p>Inactive analog of U0126(MEK-1/2 inhibitor), used as a negative control</p>Formule :C8H10N4S2Degré de pureté :98%Couleur et forme :SolidMasse moléculaire :226.32Rineterkib hydrochloride
CAS :<p>Rineterkib hydrochloride (B) is an oral RAF/ERK1/2 inhibitor for MAPK-driven cancers, including KRAS/BRAF-mutant NSCLC and CRC.</p>Formule :C26H28BrClF3N5O2Couleur et forme :SolidMasse moléculaire :614.89R18
CAS :<p>14.3.3 protein antagonist, blocks binding to Raf-1/Bad/ASK1/exoenzyme S, competitive, no phosphorylation needed, KD ~80 nM.</p>Formule :C101H157N27O29S3Degré de pureté :98%Couleur et forme :SolidMasse moléculaire :2309.69KRAS G12D inhibitor 7
CAS :<p>KRAS G12D inhibitor 7, is a highly potent inhibitor specifically targeting KRAS G12D.</p>Formule :C32H38N8O3Couleur et forme :SolidMasse moléculaire :582.709Pan-RAS-IN-6
Pan-RAS-IN-6 (compound 24) serves as a DUSP6 inhibitor, effectively reducing MAPK activation in the NCI-H1373-Luc model (DUSP6). It concurrently exhibits notable tumor growth inhibition and regression in the NSCLC brain metastasis mouse model. The compound displays high selectivity and potent inhibitory effects, particularly on KRAS mutation-associated signaling pathways. It demonstrates varied inhibitory activities against distinct KRAS mutants and their interacting proteins. The IC 50 values for KRAS G12C, G12D, and G12V are 1.3 nM, 4.7 nM, and 0.3 nM, respectively.Formule :C46H60N8O5SCouleur et forme :SolidMasse moléculaire :837.08D-JBD19
CAS :<p>D-JBD19 is a non-permeable peptide with neuroprotective effects.</p>Formule :C99H164N32O28Degré de pureté :98%Couleur et forme :SolidMasse moléculaire :2250.597KRas G12R inhibitor 1
<p>KRas G12R inhibitor 1 targets mutant cysteines in K-Ras, binds irreversibly, and is used in cancer research.</p>Formule :C39H38ClF7N6O9Couleur et forme :SolidMasse moléculaire :903.2SAH-SOS1A
CAS :<p>KRas/SOS1 inhibitor; binds KRas pocket, Kd 106-176 nM; blocks nucleotide binding; cytotoxic to KRas-driven cancers; disrupts ERK-MAPK pathway; cell-permeable.</p>Formule :C100H159N27O28Degré de pureté :98%Couleur et forme :SolidMasse moléculaire :2187.53
